{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:31:46Z","timestamp":1759422706018},"reference-count":39,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T00:00:00Z","timestamp":1184716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyse how the prescribing of cyclooxygenase\u20102 (COX\u20102) inhibitors, non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs (ns\u2010NSAIDs) and paracetamol (acetaminophen) changed when rofecoxib was withdrawn in 2004.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>COX\u20102 inhibitors, paracetamol and ns\u2010NSAID's use was measured using dispensing data for concession beneficiaries subsidized by the Australian Pharmaceutical Benefit Scheme (PBS) for the period of 1997\u20132005. Data were downloaded from the Medicare Australia website and converted, according to the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC)\/Defined Daily Dose (DDD) (2005), to DDD\/1000 concession beneficiaries\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the period 2000\u20132004, the use of COX\u20102 inhibitors was progressively increased. Overall NSAID's use changed from approximately 80 to 105\u2009DDD\/1000 concession beneficiaries\/day while a decrease of ns\u2010NSAIDs from about 70 to 40\u2009DDD\/1000 concession beneficiaries\/day was observed. Following rofecoxib withdrawal, the overall NSAIDs use declined. In 2005, celecoxib prescription declined (23%) while prescription of meloxicam increased by 62%. Use of paracetamol was steady over the period 1997\u20132004 (around 40\u2009DDD\/1000 concession beneficiaries\/day). In April 2005, a slight increase in paracetamol use was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our analysis showed that COX\u20102 inhibitors prescribing markedly influenced the overall NSAIDs prescribing in Australia. When COX\u20102 inhibitors were introduced their uptake was rapid and extensive. Following rofecoxib withdrawal, the total overall dispensing of NSAIDs returned to a similar value as before COX\u20102 inhibitors' introduction. The decrease was due both to rofecoxib withdrawal and to a reduction in celecoxib prescribing. However, meloxicam use increased. Paracetamol prescribing was steady, between 1997 and 2005 and was not affected when the COX\u20102 inhibitors were introduced on to the market and after rofecoxib withdrawal, rather than increasing as might have been anticipated after rofecoxib withdrawal. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1451","type":"journal-article","created":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T11:47:08Z","timestamp":1184759228000},"page":"1184-1191","source":"Crossref","is-referenced-by-count":25,"title":["What happened to the prescribing of other COX\u20102 inhibitors, paracetamol and non\u2010steroidal anti\u2010inflammatory drugs when rofecoxib was withdrawn in Australia?"],"prefix":"10.1002","volume":"16","author":[{"given":"Nadia","family":"Barozzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Tett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,26]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Australian Department of Health and Aging.Schedule of Pharmaceutical Benefits.2005."},{"key":"e_1_2_1_3_2","unstructured":"Food and Drug Administration.FDA Public Health Advisory: Safety of Vioxxwww.fda.gov\/cder\/drug\/infopage\/vioxx\/PHA_vioxx.htm.2004."},{"issue":"9","key":"e_1_2_1_4_2","article-title":"Recommendations for the medical management of osteoarthrits of the hip and knee","volume":"43","author":"Altman R","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_5_2","unstructured":"National Institute for Clinical Excellence.Guidance on the use of cyclo\u2010oxygenase (Cox) II selective inhibitors celecoxib rofecoxib meloxicam and etodolac for osteoarthritis and rheumatoid arthritiswww.nice.org.uk\/pdf\/coxiifullguidance.pdf.2001."},{"key":"e_1_2_1_6_2","unstructured":"National Prescribing Service.NPS News 18www.nps.org.au\/site.php?content=\/html\/news.php&news=\/resources\/NPS_News\/news18.2001."},{"key":"e_1_2_1_7_2","volume-title":"Therapeutic Guidelines: Analgesic","author":"Therapeutic Guidelines: Analgesic Writing Group","year":"2002"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2005.00015.x"},{"key":"e_1_2_1_9_2","unstructured":"BarozziN TettS.Use of non selective non steroidal anti\u2010inflammatory drugs COX\u20102 inhibitors and Paracetamol.In APSA\u2010ASCPT Melbourne 2005."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00212-X"},{"key":"e_1_2_1_11_2","unstructured":"Chiropractic Osteopathic College of Australasia.Celebrex Controversywww.coca.com.au\/newsletter\/2001\/MAR0109a.htm.2001."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058042"},{"key":"e_1_2_1_13_2","unstructured":"Food and Drug Administration.Sequence of Events with VIOXX since opening of INDhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005\u20104090B1_04_E\u2010FDA\u2010TAB\u2010C.htm.2005."},{"key":"e_1_2_1_14_2","unstructured":"Merck Sharp & Dohme.VIOXX\u00ae (rofecoxib) Information Centerwww.merck.com\/newsroom\/vioxx\/.2006."},{"key":"e_1_2_1_15_2","unstructured":"WHO. Collaborating Centre for Drug Statistics Methodology.Guidelines for ATC classification and DDD assignment.2005."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050431"},{"key":"e_1_2_1_17_2","unstructured":"Gastroenterological Society of Australia.NSAID Therapy\u2014Maximizing the Benefit Minimizing the Riskwww.gesa. org.au\/members_booklets\/nsaid\/NSAIDTherapy.pdf."},{"key":"e_1_2_1_18_2","unstructured":"Centre for Drug Evaluation and Research.Statistical Reviewwww.fda.gov\/cder\/foi\/nda\/2002\/21\u2010042S007_Vioxx_statr.pdf.2001."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21132"},{"issue":"2","key":"e_1_2_1_20_2","first-page":"1","volume":"19","author":"Australian Department of Health and Aging ADRAC","year":"2000","journal-title":"Australian adverse drug reactions bulletin."},{"issue":"5","key":"e_1_2_1_21_2","first-page":"1","volume":"22","author":"Australian Department of Health and Aging ADRAC","year":"2003","journal-title":"Australian adverse drug reactions bulletin."},{"key":"e_1_2_1_22_2","unstructured":"National Prescribing Service.NPS News 28. Minimising the risk of using analgesic for musculoskeletal pain.2003."},{"issue":"4","key":"e_1_2_1_23_2","first-page":"1","volume":"22","author":"Australian Department of Health and Aged Care ADRAC","year":"2003","journal-title":"Australian adverse drug reactions bulletin."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222120-00001"},{"key":"e_1_2_1_25_2","unstructured":"National Prescribing Service.Switching patients from Vioxx.2004."},{"issue":"10","key":"e_1_2_1_26_2","first-page":"878","article-title":"Prescribing of COX\u20102 inhibitors in Germany after safety warnings and market withdrawals","volume":"61","author":"Schussel K","year":"2006","journal-title":"Pharmazie"},{"issue":"5","key":"e_1_2_1_27_2","first-page":"637","article-title":"How did the withdrawal of rofecoxib impact on prescribing of non\u2010steroidal anti inflammatory drugs?","volume":"61","author":"Teeling M","year":"2006","journal-title":"Brit J Clin Pharmacol"},{"issue":"1","key":"e_1_2_1_28_2","first-page":"S243","article-title":"Use of Selective COX\u20102 Inhibitors in Norway before and after the withdrawal of rofecoxib\u2014Norwegian prescription database","volume":"15","author":"Furu K","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02691.x"},{"key":"e_1_2_1_30_2","first-page":"52","volume-title":"Therapeutic Guidelines Gastrointestinal","year":"2006"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1300\/J058v15n02_02"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01795.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg495"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03173.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07665.x"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.2.171"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh642"},{"issue":"11","key":"e_1_2_1_38_2","first-page":"742","article-title":"Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study","volume":"10","author":"Sebaldt R","year":"2004","journal-title":"Am J Manag Care"},{"key":"e_1_2_1_39_2","unstructured":"BrownL AbelloA PhillipsB HardingA.The Australian Pharamceuticals Benefit Scheme and Older Australians: Changes in Government Otlays and Consumer Costs from the 2002\u201303 Federal Budget Measures.www.natsem.canberra.edu.au\/conference2003\/papers\/pdf\/brown_l.pdf.2003."},{"key":"e_1_2_1_40_2","unstructured":"Australian Institute of Health and Welfare.Australia's Health.2006."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1451","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:12:37Z","timestamp":1700010757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,26]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1002\/pds.1451"],"URL":"https:\/\/doi.org\/10.1002\/pds.1451","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,26]]}}}